SPRINGFIELD, Va., Nov. 1 /PRNewswire-FirstCall/ -- VERSAR, Inc. announced today its Biodefense Laboratory has been certified for Biosafety Level 3 operations under Center for Disease Control/National Institute of Health (CDC/NIH) requirements. The certification allows the Biodefense Laboratory to work with microorganisms and toxins requiring BSL-3 containment in support of homeland security, biodefense and biotechnology programs.
The Company also announced that Dr. Claudia Benack has become the Biodefense Laboratory Director. Dr. Benack has over 25 years of experience in biological and biochemical programs, including BSL-3 work involving U.S. Department of Defense biodefense programs. Dr. Benack holds a Ph.D. in biochemistry and microbiology and was an NIH Postdoctoral Fellow in Biochemistry.
Dr. Ted Prociv, President and CEO of Versar stated, “Achieving this certification and the assignment of Dr. Benack as Director are critical milestones in our plan to expand work in the biodefense arena, which is major focus of the U.S. strategy to counter terrorist threats. We foresee additional opportunities to participate in protecting the Country from biological and other threats from ‘weapons of mass destruction’.”
Versar, Inc., headquartered in Springfield, VA, is a publicly held professional services firm supporting government and industry in national defense/homeland defense programs, environmental health and safety and infrastructure revitalization. Versar operates a number of web sites, including the corporate Web sites, http://www.versar.com/, http://www.homelanddefense.com/, and http://www.geomet.com/; and a B2B portal for homeland defense products and services, http://www.nbcprotect.com/ and http://www.dtaps.com/ .
This press release contains forward-looking information. The forward- looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly impacted by certain risks and uncertainties described herein and in Versar’s Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended June 30, 2004.
Contact: James Dobbs (703) 642-6712 Senior Vice President Email: jdobbs@versar.com Investor Relations Contact: Andrew J. Kaplan (732) 747-0702 Barry Kaplan Associates 623 River Road Fair Haven, NJ 07704 Email: smallkap@aol.com
Versar, Inc.,
CONTACT: James Dobbs, Senior Vice President of Versar, +1-703-642-6712,jdobbs@versar.com; or Andrew J. Kaplan, Investor Relations Contact of BarryKaplan Associates, +1-732-747-0702, smallkap@aol.com, for Versar